Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, Experiments, Research, Analysis, Overview H1 2019

Posted on 2019-04-02 by Mark Hub in Healthcare // 0 Comments

Albany, US, 2019-Apr-02 — /EPR Network/ —This research study added to the broad database of Market Research Hub (MRH) focusing on the Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2019 delivers an in-depth outlook to present information about executive summary and key performance indicators. Furthermore, readers can gather knowledge about the economic status, demographics and competitive landscape which is prevailing in the concerned industry during the review period, 2019. Overall, the purpose of this assessment is to present a clear picture highlighting the transformations expected to occur in the Severe Acute Respiratory Syndrome (SARS) driven by major trends and opportunities.

Get Sample Copy of This Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2197329

Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2019

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2019, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

BROWSE Full Report NOW @ https://www.marketresearchhub.com/report/severe-acute-respiratory-syndrome-sars-pipeline-review-h1-2019-report.html

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) – Overview
Severe Acute Respiratory Syndrome (SARS) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Severe Acute Respiratory Syndrome (SARS) – Companies Involved in Therapeutics Development
3-V Biosciences Inc
Abhelix LLC
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Fabentech SA
GeneCure LLC
Gilead Sciences Inc
Novavax Inc
Oncovir Inc
Phelix Therapeutics LLC
Severe Acute Respiratory Syndrome (SARS) – Drug Profiles
ATR-006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSW-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
More Information………@@@

Enquire about this Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2197329

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Healthcare market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick